Amy Barton Pai - UM College of Pharmacy · Amy Barton Pai. Home Address Work Address 2222 New Scotland Road Albany College of Pharmacy . Voorheesville, NY 12186 and Health Sciences

Amy Barton Pai

Home Address Work Address 2222 New Scotland Road Albany College of Pharmacy Voorheesville, NY 12186 and Health Sciences

106 New Scotland Avenue O’Brien 232 Albany, NY 12208 Tel: (518) 694-7203 [email protected]

FACULTY APPOINTMENTS

October 2014-present Professor with Tenure Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences Albany, New York

October 2008-October 2014 Associate Professor

Department of Pharmacy Practice Albany College of Pharmacy and Health Sciences Albany, New York

July 2010-present Adjunct Associate Professor of Internal Medicine

Division of Nephrology and Hypertension Albany Medical College Albany, New York

July 2007-September 2008 Associate Professor of Pharmacy and Nephrology with Tenure

University of New Mexico College of Pharmacy and School of Medicine Albuquerque, New Mexico

August 2001-June 2007 Assistant Professor of Pharmacy and Nephrology

University of New Mexico College of Pharmacy and School of Medicine Albuquerque, New Mexico

EDUCATION

2015-present Arizona State University Master of Healthcare Innovation

1997-1999 Albany College of Pharmacy, Albany, New York

Doctor of Pharmacy, magna cum laude

mailto:[email protected]

Amy Barton Pai, Pharm.D.

2

1993-1996 Albany College of Pharmacy, Albany, New York

Bachelor of Science in Pharmacy, cum laude 1991-1993 Dutchess Community College, Poughkeepsie, New York

Chemistry major CERTIFICATION

December 2003 Board Certified Pharmacotherapy Specialist Re-certified 2010

April 2012 Medication Therapy Management

LICENSURE

1996 New York- 044397 1999 Illinois- 051-287158 (inactive) 2001 New Mexico- RP00006435 (inactive)

RESIDENCY/FELLOWSHIP EXPERIENCE

1999-2001 Nephrology Fellowship University of Illinois at Chicago, Chicago, IL Mentor: Alan Lau, Pharm.D.

1996-1997 Pharmacy Practice Residency

St. Peter’s Hospital, Albany, New York Residency Director: Thomas Lombardi, Pharm.D.

PROFESSIONAL EXPERIENCE

1997-1998 Relief Pharmacist Price Chopper Pharmacy Albany, New York

1996-1999 Per Diem Staff Pharmacist

St. Peter’s Hospital Albany, New York 1993-1996 Pharmacy Intern/Pharmacist

Red Hook Drug Store, Red Hook, New York 1993-1995 On-Line Service Representative

Pharmacy Service Corporation of New York, Albany, New York 1989-1993 Pharmacy Technician

CVS Pharmacy, Hyde Park, New York CLINICAL SERVICE

October 2014-present Nephrology Pharmacotherapy Specialist Transitions in Care Program Dialysis Clinic Inc, Capital Region Network Saratoga, Clifton Park, Troy, NY

June 2011-Oct 2014 Nephrology Pharmacotherapy Specialist

Rubin Dialysis/ MyMedZ MTM service Troy, NY


3

Aug 2010-Jan 2013 Nephrology Pharmacotherapy Specialist

Renal Consult Service Albany Medical Center Hospital, Albany, NY

Feb 2009-May 2011 Albany Regional Kidney Center

Hemodialysis Unit Provide pharmaceutical care to 180 patients

Dec 2004-Oct 2008 Nephrology Pharmacotherapy Specialist

University of New Mexico Chronic Kidney Disease (CKD) clinic Triage patients, recommend optimal therapies, screen for anemia and secondary hyperparathyroidism.

Aug 2001-Oct 2008 Nephrology Pharmacotherapy Specialist

Dialysis Clinic, Inc. outpatient hemodialysis unit, Albuquerque, NM Provide pharmaceutical care to 175 patients, participate in weekly and monthly rounds, initiate and revise drug policy and procedures, provide inservices to staff.

PUBLICATIONS

Original Research

*indicates corresponding author

1. *Pai AB, Neumann P, Narsipur S, Goldstein L, Johnson A. Lipoteichoic acid as a Non-Invasive Measure of Biofilm Burden in Hemodialysis Patients. (In preparation)

2. *Pai AB, Meyer D, Bales B, Cotero V, Pai MP, Zheng N, Jiang W. Performance of redox active

and chelatable iron assays to determine labile iron release for intravenous iron formulations. (Submitted: Clin Pharmacol Ther)

3. *Pai AB, Grabe DW, Eisele G, Patel H, Kubotera S, Prokopienko A, Nolin T. Biomarkers of

inflammation and vascular reactivity in CKD Stage 3 and 4 patients receiving paricalcitol. (Submitted: Journal of Research and Development)

4. Jang S, Prokopienko AJ, Grabe DW, Cerulli J, Fox C, Vassalotti J, *Pai AB. NSAID-Avoidance

Education in Community Pharmacies for Patients at High Risk for Acute Kidney Injury, Upstate New York, 2011. Prev Chronic Dis. 2014 Dec 18;11:E220 PMID:25523351

5. *Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H, Merrill D, Ali AS, Pai AB,

Waldman J, Salman L. Prevalence of Chronic Kidney Disease in Patients Undergoing Cardiac Rhythm Device Removal. Semin Dial. Semin Dial. 2013 Jan-Feb;26(1):111-3 PMID: 22780814

6. *Barton-Pai A, Patel H, Prokopienko A, Gertzberg N, Alsaffar H, Neumann P, Punjabi A,

Johnson A. Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species. Plos One 2012;7(11):e49209 PMID: 23166614

7. Conner TA, McQuade CR, Olp J, *Pai AB. Effect of Intravenous Vitamin C on Reactive Oxygen

Species Generation, Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). Biometals. 2012 Oct;25(5):961-9 PMID: 22706571

8. Pai AB. Feleder C, *Johnson A. Tumor Necrosis Factor-α (TNF) induces increased lung vascular

permeability: a role for GSK3α/b. Eur J Pharmacol. 2011 Apr 25;657(1-3):159-66 PMID: 21316358


4

9. *Pai AB, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine

Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals. 2011 Aug;24(4):603-13 PMID: 21229380

10. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, *Pai AB. Effect of different intravenous iron preparations

on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 2010:11;16 PMID: 20716362

11. *Pai AB, Nielson JC, Kausz A, Miller P, Owen J. Plasma Pharmacokinetics of two consecutive

doses of ferumoxytol in Healthy Subjects. Clin Pharmacol Ther 2010;June 30:1-5 PMID: 20592725

12. *Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use

Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care- a 2 year randomized, controlled study. Pharmacotherapy 2009;29(12):1433-1440 PMID: 19947803

13. Demirovic J, Pai AB, Pai MP. Creatinine Clearance Estimation in Morbidly Obese Patients. Am J

Health Syst Pharm 2009;66(7)642-648 PMID: 19299371 14. Boyd A, McQuade CR, Conner TA, Manley HJ, *Pai AB. Correlation between the Renal Quality

of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int 2009;89-90 PMID: 19210284

15. *Pai AB, Boyd A, Chavez A, Manley HJ. Health-related Quality of Life is Maintained in

Hemodialysis Patients Receiving Pharmaceutical Care-A 2-Year Randomized, Controlled Study. Hemodial Int; 2009;13:72-79 PMID: 19210281

16. *Pai AB, Norenberg JP, Boyd A, Raj DSC, Chan L. Intravenous Iron is Associated with Increased

Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients. Clin Ther 2007;29:2699-2705 PMID: 18201586

17. *Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP, Zager P. Comparison of oxidative

stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy 2007;27:343-350. PMID: 17316146

18. Boyd AV, Townsend K, Dunne A, Spalding CT *Pai AB. Optimal sampling for international

normalized ratios in hemodialysis patients with central venous catheters. Nephrol Nurs J 2006;33:408 PMID: 17001998

19. *Barton Pai A, Depczynski J, Pai MP, McQuade C, Mercier RC. Non‑transferrin bound iron is

associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304‑309 PMID: 16809897

20. Raj DSC, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P:

Skeletal muscle, cytokines and oxidative stress in End-stage renal disease. Kidney Int 2005;68:2338-2344 PMID: 16221238

21. *Pai AB, Pai MP. A limited sampling algorithm for vancomycin dosing during hi-flux hemodialysis.

Am J Health Syst Pharm 2004;61:1812-6 PMID: 15462252 22. *Barton Pai A, Lin S, Arruda J, Lau AH. Long-term therapy with paricalcitol for secondary

hyperparathyroidism in hemodialysis patients. Int J Artif Organs 2003;26(6):484-90 PMID: 12866654


5

23. *Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients Clinical Nephrology 2002;58:38-46 PMID: 12141405

24. Barton AE, Levin GM. Evaluating the incidence of antidepressant-induced sexual dysfunction

Hospital Pharmacy 2000 Jun:35(6);609-613 Case Reports

1. McQuade CM, Griego J, Anderson J, *Pai AB. Dose-dependent elevation in serum creatinine associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65:138-41 PMID: 18192258

2. Carson J, Gold L, Barton A, Biss R. Fatality and interferon alpha for malignant melanoma.

Lancet (letter) 1998 Oct 31; 352(9138): 1443-4 PMID: 9807998

3. Barton A Burns, Bailie GR, Eisele G, McGoldrick D, Rosano TG, Swift T. Use of pharmacokinetics to determine the duration of dialysis in management of methanol poisoning Am J Emerg Med. 1998 Sep;16(5):538-40 PMID: 9725978

Review Articles and Editorials

1. *Pai AB, Teoh B, Cardone K. Expanding the Role of Pharmacy Technician: Value to Provision of Medication Management Services in Hemodialysis Units. (Submitted: Journal of Pharmacy Practice)

2. Gilmartin C, Pai AB, Hughes D, Hilal N. Risky business: Lessons from medication misadventures

in chronic kidney disease. Physician Assistant Clinics (Under Review: Physician Assistant Clinics)

3. *Pai AB, Jang S, Wegryzn N. Iron-based Phosphate Binders-A New Element for Treatment of Hyperphosphatemia in Kidney Disease. (Under Review: Expert Opinion in Metabolism and Toxicology)

4. *Pai AB. Keeping Kidneys Safe: The Pharmacist’s Role in NSAID Avoidance in High-Risk

Patients. J Am Pharm Assoc (2003). 2015 Jan 1;55(1):e15-25 PMID:25503987

5. *Pai AB. Evaluating Plasma Pharmacokinetics of IV Iron Formulations: Judging Books by Their Covers? Clin Pharmacokinet 2015:54(4);323-4

6. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, On behalf of

the American Society of Nephrology Dialysis Advisory Group. Considerations and Challenges in Defining the Optimal Utilization of Iron in Dialysis-Dependent Chronic Kidney Disease. Invited Commentary, J Am Soc Nephrol. 2015;26(6):1238-1247 PMID:25542967

7. Manley HJ, Barton-Pai AB. Integrated Pharmacy Services: a necessary component for ESRD

patient care. Am J Kidney Dis 2013; Sep;62(3):445-7 PMID: 23972057

8. *Pai AB, Cardone KE, Manley HJ, St. Peter W, Shaffer R, Somers M, Mehrotra R. Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach. Clin J Am Soc Nephrol. Invited Commentary. 2013 Nov;8(11):1988-99 PMID: 23990162

9. *Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney

disease: or another dark cloud? Journal of Blood Medicine 2012;3:77-85 PMID: 22973119

10. Kubotera N, Prokopienko A, Garba AO, *Pai AB. Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status. Int J Nephrol. 2013;2013:954956. PMID: 2340177


6

11. Moore CL, *Pai AB. CKD: Pharmacotherapy in a House of Mirrors. (editorial) Adv in Chronic Kidney Dis. 2010;17:381-83 PMID: 20727507

12. Cardone KE, Bacchus S, Assimon M, *Pai AB, Manley HJ. Medication-Related Problems in

Chronic Kidney Disease. Adv in Chronic Kidney Dis 2010;17:404-412 PMID: 20727510

13. Assimon M, Mousa S, Shaker O, *Pai AB. The Effect of Sevelamer Hydrochloride and Calcium Based Phosphate Binders on Mortality in Hemodialysis Patients: A Need for More Research. Consultant Pharm. 2010;35:37-51 PMID: 20211816

14. *Barton Pai AB, Conner TA, McQuade CR. Therapeutic Use of the phosphate binder Lanthanum

Carbonate. Expert Opin Drug Metab and Toxicol 2009; 5 (1):71-81 PMID: 19236230

15. *Pai AB, Conner TA. Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D. J Pharm Prac 2008;21:214-224

16. Pai AB. Broader Roles of Vitamin D in Patients with Chronic Kidney Disease. Kidney: A Current

Survey of World Literature. 2006;15:199-201

17. Pai AB, Pai MP. Optimizing Antimicrobial Therapy for Gram-positive Bloodstream Infections in Patients on Hemodialysis. Adv in CKD 2006; Jul;13(3):259-70 PMID: 16815231

18. Martinez I, *Pai AB. Use of antibiotic lock solutions in hemodialysis catheter-related bloodstream

infections. Kidney: A Current Survey of World Literature. 2005;14:53-56

19. *Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney disease outcome quality initiative (K/DOQI) for hyperphosphatemia. Curr Med Res Opin. 2004;20:991-999 PMID: 15265243

20. *Pai AB. Intravenous iron and bacteremia in hemodialysis patients. Kidney: A Current Survey of

World Literature. 2004;13:51-53

21. *Pai AB. Warfarin for prevention of vascular access thrombosis in hemodialysis patients. Kidney: A Current Survey of World Literature. 2003;12:201-203

22. *Pai AB. Iron and oxidative stress. Kidney: A Current Survey of World Literature. 2003;12:53-56

23. Smith HS, Barton AE. Tizanidine in management of spasticity and musculoskeletal complaints in the palliative care population. American Journal of Hospice and Palliative Care 2000 Jan/Feb:17(1);50-58 PMID: 11094920

ABSTRACTS

*presenting author, !student/trainee author

1. *!Raouf M, !Kelsey T, !Wilming C, Cabral K, LaFleur C, Pai AB. A student pharmacist-led public health initiative for early identification of cardiovascular and kidney disease risk factors. American College of Clinical Pharmacy Global Conference, October 19, 2015, San Francisco, CA.

2. *Pai AB, Narsipur S, Goldstein L. Lipoteichoic Acid As A Non-Invasive Marker Of Biofilm Burden

In Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27, 2015


7

3. *Pai AB, Meyer D, Bales B, Cotero V, Pai A, Zheng N, Jiang W. Labile Iron Release From

Intravenous (IV) Iron Formulations: Considerations For Bioequivalence. National Kidney Foundation Spring Clinical Meeting. March 27, 2015

4. *Pai AB, Cardone K, Daoui R, Salenger P, Chen X, Kao T, Boverman G, Davenport D.

Utility Of Bioelectrical Impedance Spectroscopy (BIS) With Electrical Impedance Tomography (Eit) To Evaluate Regional Volume Flux In Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27, 2015

5. *Pai AB, Meyer D, Bales B, Cotero V, Pai M, Zheng N, Jiang W. Performance of redox active and

chelatable iron assays to determine labile iron concentrations from intravenous iron formulations. Innovation@CDER, Center for Drug Evaluation and Research, September 10, 2014, Silver Spring, MD

6. Assessing Literacy and Numeracy Skills Relating to Medication Labeling in Patients on Dialysis.

*!Cho S, Parker W, !Teoh B, Pai AB, Cardone KE. National Kidney Foundation Spring Clinical Meeting. Las Vegas, NV April 23, 2014

7. *Pai AB, !Garba AO, Waldman J. A Non-Invasive Approach to Evaluation of Biofilm Burden in

Hemodialysis Patients. American Society of Nephrology Renal Week. November 6, 2013. Atlanta, GA

8. !Peres de Alcantara D, *!Prokopienko AJ, Cardone K, Pai AB. Medication Management

Services for Dialysis Patients in Brazil-A Survey of Clinicians. American College of Clinical Pharmacy, October 14, 2013, Albuquerque, NM.

9. *!Prokopienko A, !Lawuyi A, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect of

IV Iron Compounds on Intracellular Labile Iron Pool in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacology. Bethesda, MD. September 20, 2013.

10. Cardone KE, Parker W, *Pai AB, Cavanaugh K. Assessment of medication label literacy and

numeracy skills in hemodialysis patients. National Kidney Foundation 2013 Spring Clinical Meeting, April 2-6, 2013; Orlando, FL. Poster #117; Poster presentation.

11. *!Patel H. !Kubotera N, !Prokopienko A. Cardone KE, Pai AB. Usage of Erythropoiesis

Stimulating Agents Pre and Post Bundle. American Society of Health-systems Pharmacists Mid- Year Clinical Meeting, December 7, 2011, New Orleans, LA

12. *!Patel HV, !Prokopienko AJ, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect

of IV Iron Compounds on Intracellular Reactive Oxygen Species (ROS) Generation in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacy Annual Meeting (Best Student Paper Finalist). October 17, 2011, Pittsburgh, PA

13. *Cardone KE, !Fox B, Meola S, Goldstein L, Hoy C, Salenger P, Pai AB. Effects of the ESRD

Medicare Bundling Rule on Anemia Management in Private Dialysis Units. American Society of Nephrology Renal Week. November 11, 2011, Philadelphia, PA

14. *Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Cell

Adhesion Markers and ADMA in CKD 3 and 4. ERA-EDTA Annual Meeting, June 24, 2011, Prague, Czech Republic

15. *!Sidile J, !Der Mesorpian P, !Makary Y, Pai AB, Haqqie S. Evaluation of Predictive Factors of

Potassium Derangement in Therapeutic Hypothermia. National Kidney Foundation, Spring Clinical Meeting. April 27, 2011, Las Vegas, NV


8

16. *Pai AB, Johnson A, Role of Intravenous Iron Compounds in Pathogenesis of Pulmonary Edema.

ASN Renal Week, November 17-21, 2010, Denver, CO 17. *Pai AB, Johnson A. Lipoteichoic Acid (LTA) Induced Lung Endothelial Barrier Dysfunction:

Possible Role of Endothelial Nitric Oxide (eNOS). ASN Renal Week, November 17-21, 2010, Denver, CO

18. *Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Biomarkers

of Vascular Reactivity in CKD 3 and 4. ASN Renal Week, November 17-21, 2010, Denver, CO

19. Johnson A, *Pai A. Lipotechoic acid (LTA) causes reactive oxygen species dependent lung endothelial barrier dysfunction. American Thoracic Society, May 17, 2010, New Orleans, LA

20. *Pai AB, Gertzberg N, Neumann P, Johnson A. Role of Lipotechoic acid from Staphylococcus

aureus in Pathogenesis of Pulmonary Edema. ASN Renal Week, October 30, 2009, San Diego, CA

21. Conner T, Raj D, McQuade C, Olp J, *Pai AB, Effect of Intravenous Ascorbic Acid on Cytokine

Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA

22. *Pai AB, Raj D, !McQuade C, Olp J. !Hicks P, !Conner T. Non-transferrin Bound Iron (NTBI),

Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA

23. *Pai AB, Owen J, Clarkin M, Nielson J, Clark T. Lawler D, Kausz A. Plasma Pharmacokinetic

(PK) Profile of Ferumoxytol in Healthy Subjects. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA

24. *!Boyd A, !McQuade CR, Manley HJ, Pai AB. Correlation between the Renal Quality of Life

Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Abstract SU−PO1099. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA

25. *!Demirovic J, Pai AB, Conner TC, Pai M. Comparison of Nafcillin and Cefazolin for Methicillin

Sensitive Staphylococcus aureus (MSSA) Related Bloodstream Infections (BSI) in Hemodialysis (HD) Patients. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA

26. *!McQuade CR, !Boyd AV, !Conner T, Pai AB. Clinical pharmacy research training program

(CPRTP): a longitudinal approach to career development. Abstract # 268. Annual Meeting of the American College of Clinical Pharmacy. October 16, 2007. Denver, CO

27. *Pai AB, Norenberg JP, !Boyd AV, Raj DSC, MD, Chan L, Intravenous Iron is Associated with

Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients J Am Soc Nephrol 2006;17:481A

28. *!Horton E, Pai AB, Anselmo L, Garcia D. Case-control analysis of prophylactic enoxaparin

therapy in obese patients. American College of Clinical Pharmacy, October 28, 2006 St. Louis, MO

29. *!McQuade C, !Boyd A, !Chavez A, !Burke R, Pai AB. Factors associated with hypocalcemia

in hemodialysis patients receiving cinacalcet HCL for secondary hyperparathyroidism. American College of Clinical Pharmacy, October 29, 2006 St. Louis, MO


9

30. *Pai AB, !Depczynski JC, !Martinez I, !Boyd A, !Chavez A, Manley HJ. Impact of Clinical

Pharmacy Services on Medication Costs, Hospitalization Rates and Drug-Related Problems in Hemodialysis (HD) Patients. J Am Soc Nephrol 2005;16:725A

31. *Pai AB, Pai M, Raj DSC. Hemodialysis Clearance of Amino Acids (AA) during Intradialytic

Supplementation. J Am Soc Nephrol 2005;16:717A 32. *Pai AB, !Adeniyi O, Osman F, Shah V, Ferrando A, Raj DSC. Amino Acid and Protein Kinetics

in ESRD Patients with Type-2 Diabetes Mellitus. J Am Soc Nephrol 2005;16:714A 33. *Osman F, !Adeniyi O, Varghese E, Shah V, Waters D, Pai AB, Ferrando A, Raj DSC. Amino

Acid Infusion Does Not Decrease Protein Catabolism during Hemodialysis. J Am Soc Nephrol 2005;16:48A

34. *Pai AB, Pai M, !Depczynski JC, !McQuade C, Mercier RC. Effect of Non-Transferrin Bound

Iron on Staphylococcus aureus Growth in Hemodialysis Patients Receiving Intravenous Iron Sucrose. J Am Soc Nephrol 2005;16:453A

35. *Pai AB, !Boyd A, !Chavez A, Manley HJ. Assessment of quality of life in hemodialysis patients

receiving pharmaceutical care. Pharmacotherapy 2005;25:1466 36. *Pai AB, Harford A, !Boyd A, !McQuade C, Zager P. Comparison of Oxidative Stress Markers in

Hemodialysis (HD) Patients Receiving Iron Dextran (ID), Sodium Ferric Gluconate (SFG) and Iron Sucrose (IS). Pharmacotherapy 2005;25:1513

37. *!Martinez I, Pai AB. Frequency of Hyperkalemia in Hemodialysis Patients on Angiotensin-

Converting Enzyme Inhibitors (ACE-I) and Angiotensin Receptor Blocker Therapy. American College of Clinical Pharmacy, Spring Meeting, April 12, 2005, Myrtle Beach, SC.

38. *!Calhoun W, Pai A, Morgan M, Pickett G, Shah V, Raj D. Skeletal Muscle Is an Important

Source of Interleukin-6 and Oxidative Stress in End-Stage Renal Disease (ESRD) J Am Soc Nephrol 2004;SAPO790

39. *!Depczynski JC, Pai AB, Boyd A, Manley HJ. A Randomized Study to Determine the Impact of

Clinical Pharmacy Services on Medication Costs, Hospitalization Rates and Quality of Life in Hemodialysis Patients. American Society of Helath-Systems Pharmacists Mid-year meeting. December 11, 2003. New Orleans, LA

40. *Harford A, Stidley C, Hunt C, Paine S, Pai AB, Scavini M. Brown R, Zager P. Iron Dose and

Survival in Hemodialysis Patients. J Am Soc Nephrol 2003:14;266 41. *!Boyd A, Pai AB, Townsend K, Tinklenberg A, Spalding CT. Optimal Sampling for International

Normalized Ratios in Hemodialysis Patients with Central Venous Catheters. J Am Soc Nephrol 2003:14;729A

42. *Stidely CS, Sun Y, Harford A, Brown R, Pai AB, Zager PG. Increased mortality in hemodialysis

patients receiving no iron and high dose iron therapy. Abstract # 554358 World Congress of Nephrology, Berlin, Germany. June 8-12 2003

43. *Pai AB, Brown R, Spalding CT, Zager P. Clotting events within target INR ranges in

hemodialysis patients treated with warfarin. (Abstract # F-PO826) J Am Soc Nephrol 2002:13;229A

44. *Pai AB, Lin S, Arruda J, Lau A. Long-term therapeutic effects of paricalcitol in hemodialysis

patients. (Abstract # A0304) J Am Soc Nephrol 2000:11;56A


10

45. *Pai AB, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. (Abstract # 153) American College of Clinical Pharmacy Annual Meeting Los Angeles, CA November, 2000

46. *Pai AB, Lin S, Lau AH. Evaluating Long-term therapy with paricalcitol in hemodialysis patients.

(Abstract # 190) American College of Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA April 2000

47. *Lin S, Pai AB, Lau AH. Correlation of patient variables to abnormal lipid profiles in the

hemodialysis population. (Abstract # 189) American College of Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA April 2000

48. *Barton AB, Carson J, Lombardi TP. Evaluating Diuretic Resistance and Implementation of

Therapeutic Substitution; Torsemide for Bumetanide. (Abstract #150) 16th Annual Conference for Pharmacy Residents and Preceptors, Baltimore, MD May 1997

OTHER PUBLICATIONS

1. Wilkerson T, Pai AB. Optimizing Pharmacotherapy in Chronic Kidney Disease– The Role of the Clinical Pharmacist. Pharmacist Quarterly, Phoenix Indian Medical Center. March 2007

2. Ault A. Preventing ESRD Drug Interactions. Internal Medicine News. January 15, 2006. (press

release based on abstract presented at American Society of Nephrology Meeting, November 2005)

3. Pai AB. Summary of Recent Studies of Dual Blockade of the Renin-Angiotensin-Aldosterone-

System with ACE-inhibitors(ACEI) and Angiotensin Receptor Blockers(ARB) in Diabetic Kidney Disease. American College of Clinical Pharmacy Nephrology PRN Newsletter. July 2005

4. Martinez I, Pai AB. Antibiotic Lock Solutions for Hemodialysis Catheter-related Bloodstream

Infections. American College of Clinical Pharmacy Nephrology PRN Newsletter. March 2005

5. Koertner B, Pai AB, Impact of National Kidney Foundation Kidney Disease Outcome Quality Initiative Guidelines on Treatment of Renal Osteodystrophy in Hemodialysis Patients. American College of Clinical Pharmacy Nephrology PRN Newsletter. March 2004

6. Ponto JA, Pai AB (guest editor).Radiopharmaceuticals and Dialysis. Correspondence Continuing

Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. 2002;10(1):1- 37

7. Pai AB. Lead in Calcium Supplements. American College of Clinical Pharmacy Nephrology PRN

Newsletter. September 2002

8. Barton AB, Carson J. The clinical use of loop diuretics in congestive heart failure and chronic renal insufficiency. Therapeutic Forum-St. Peter’s Hospital, October 1996

BOOK CHAPTERS

1. Pai AB. Iron Oxide Nanoparticles for Treatment of Anemia of Chronic Kidney Disease: Too Much of a Good Thing? R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors): Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk, Pan Stanford Publishing, Singapore (2015) [ISBN 978-981-4669-22-1]


11

2. Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A Pathophysiologic Approach, Ninth edition, DiPiro J et al eds. Mcgraw Hill. 2013

3. Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A

Pathophysiologic Approach, Eighth edition, DiPiro J et al eds. Mcgraw Hill. 2010

4. Pai AB, Mason DL. Acute Kidney Diseases. in Tisdale J, Miller D. Drug-Induced Diseases, Prevention, Detection and Management. 2nd edition, 2010 American Society of Health-systems Pharmacists. Bethesda, MD.

5. Pai AB, Pai MP. Acute Renal Diseases. in Tisdale J, Miller D. Drug-Induced Diseases,

Prevention, Detection and Management. 2005 American Society of Health-systems Pharmacists. Bethesda, MD.

6. Pai AB, Rohrschieb M. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A

Pathophysiologic Approach, Seventh edition, DiPiro J et al eds. Mcgraw Hill. 2008

7. Pai AB, Conner TC. Chronic Kidney Disease in Applied Therapeutics: The Clinical Use of Drugs. 9th Edition, Koda-Kimble et al eds. Lipincott Williams and Wilkins. 2008

GRANTS AWARDED

2014 A pilot study of monitoring hydration level in hemodialysis patients with multi-channel electrical impedance tomography. General Electric Global Research Cardone KE (PI), Pai AB (Co-PI), $25,000

2013 An in vitro-in vivo correlation model to predict serum non-transferrin bound iron from intravenous

iron compounds. NIH 1U01FD004889, Pai AB (PI) Pai MP, Meyer D, Bales, B (Co-Is), $499,999 2011 Use of a simple immunoassay to quantitatively assess catheter biofilm to predict systemic

inflammatory burden and catheter-related bloodstream risk. Dialysis Clinic Inc. Paul Teschan Research Fund. Pai AB (PI). Mousa S (Co-I), Waldman J (Co-I), Harford A (Co-I), $100,000

2008 Development of a Pilot Chronic Kidney Disease Biomarker Surveillance Cohort: The Albany

Pharmacy Biosurveillance (Alpha-Bios) Cohort Study. Scholarship of Discovery, Pai AB (PI), Mason DL, (Co-PI), Grabe DW, Pallotta K, Cheng M (Co-Is), $6,000

Effects of 19-nor-1α-dihydroxyvitamin D2 (paricalcitol) versus placebo on oxidative stress and vascular reactivity in CKD patients. Abbott Laboratories. Pai AB (PI), Grabe D, Mason DL Eisele G (Co-Is), $108,000

2006 Effect of Intravenous Ascorbic Acid on Oxidative Stress and Cytokine Activation in Hemodialysis

Patients on Intravenous Iron. Pai AB (PI), Conner TA Co-I, Raj DSC, Co-I University of New Mexico General Clinical Research Center, $6,982

Cytokine Activation and Oxidative Stress in Hemodialysis Patients Receiving IV Iron. American College of Clinical Pharmacy and University of New Mexico General Clinical Research Center, Pai AB (PI), Raj DSC (Co-I), $23,500

Cytokine Activation, Oxidative Stress and Mitochondrial Toxicity Associated with IV Iron Use in Patients on Hemodialysis. Clinical Translational Science Center Pilot Project RFA. Pai AB (PI) Raj DSC, Walker MK, Shah VO. (Co-Is) $50,000


12

2005 Accuracy of creatinine clearance equations in morbidly obese patients: Influence of central body

fat distribution. University of New Mexico General Clinical Research Center Pai MP (PI), Pai AB (Co-I), Demirovic J (Co-I), $3,080.

2004 Effects of Intravenous Iron Sucrose on the Rate of Staphylococcus aureus Growth in Uremic

Serum. University of New Mexico Resource Allocation (RAC) Grant. Pai AB (PI), MP Pai (Co-I), Mercier RC (Co-I), Depczynski JC (Co-I) $10,000

2003 Comparison of Markers of Oxidative Stress in Hemodialysis Patients Receiving Iron Dextran,

Sodium Ferric Gluconate and Iron Sucrose. American College of Clinical Pharmacy Anemia Research Award and University of New Mexico General Clinical Research Center, Pai AB (PI), Zager P (Co-I), Zager R, (Co-I), Norenberg JP (Co-I), $20,946

2002 Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in

Hemodialysis Patients. Health Outcomes Research Starter Grant, PhRMA Foundation, (2 years) Pai AB (PI), HJ Manley (Co-PI), $60,000

Cytochrome P-450 3A4 Activity in Iron Deficient Hemodialysis Patients with Diabetes Mellitus, University of New Mexico General Clinical Research Center, Pai AB (PI), Spalding CT (Co-I), Norenberg JP (Co-I), $11,831

Grants Submitted

2015 Daptomycin pharmacokinetics in home hemodialysis patients. Paul Teschan Research Fund.

Dialysis Clinic Inc. Cardone K (PI), Pai AB (Co-I), Salenger P (Co-I). $50,000, Submitted: June 30, 2015, under review

A Community Based Study of Adverse Effects of NSAIDs on the Kidney and Risk Mitigation To Reduce Preventable Harm. FDABAA-15-00121 AB Pai (PI) $203,733, Submitted: June 29, 2015, under review

2013 Quantitative Hydration Assessment during Hemodialysis Using Multi-frequency and Multi-channel

Electrical Impedance Technologies. NIH R21 PA-13-303. Chen X (PI), Pai AB, Cardone K (ACPHS subawardees, total subaward $181,260). Status: Scored/Not funded

Addressing the Source of Catheter-related Inflammation: Inhibition of Lipoteichoic Acid Synthesis in Catheter Biofilm with Daptomycin-Anticoagulant Antimicrobial Lock Solutions. Normon S Coplon, Satellite Healthcare, Pai AB (PI), Nicasio (Co-I) $150,000 Status: Not Funded

2012 Medication management by PHArmacists for patients on dialySIS (The EMPHASIS Program),

Centers for Medicaid and Medicare Healthcare Innovation Award. $6,839,544 (total). Cardone K (PI), Pai A (Co-PI) Status: Not Funded

2011 Gram-positive vascular access infection in frequent home hemodialysis. Cardone K (PI), Pai AB

(Co-I). Baxter Renal Discoveries EGP Grant Program. $375,000 (direct) Status: Not Funded

Pharmacists Reduce Kidney Disease Risks-the PreCKD Program. Pai AB (PI), Cerulli J, Grabe DW, Polimeni J (Faculty Investigators). NIH R15, $300,000 (direct). Status: Not Discussed, Not Funded

Pharmacists Reduce Kidney Disease Risks-the PreCKD Program. Pai AB (PI), Cerulli J, Grabe DW, Polimeni J (Faculty Investigators). NIH R34, $450,000 (direct). Status: Scored/Not Funded


13

2010 Comparison of Maintenance Doses of Iron Sucrose on Biomarkers of Oxidative Stress,

Inflammation and Vascular Reactivity. Pai AB (PI), Bailie GR, Mason DL. Fresenius Medical Care. $210,000, Status: Not Funded

2009 Catheter Biofilm and Lung Injury in CKD Stage 5. Pai AB, (PI), Johnson A. National Kidney

Foundation KDOQI Research Grant. $450,000. Status: Not Funded

A mechanism for lipoteichoic acid-induced lung injury. Pai AB, (PI), Johnson A, (Faculty Investigator). NIH R15 (AREA). $300,000 Status: Scored but not funded

Lipoteichoic acid -induced lung edema during iron supplementation. Johnson A (PI), Pai AB (PI), NIH RC2 (Global Opportunities). $1,300,000. Status: Not Discuss/Not Funded

Inflammation, Vascular Reactivity and Contractility after Chronic Administration of Intravenous Iron Compounds. Pai AB (PI), Johnson A Co-I, Bailie G (Co-I), AMAG Pharmaceuticals. $185,899 Status: Not Funded

2007 Effect of Relatively Labile and Stable Iron-Carbohydrate Complexes on Cardiomyocyte

Mitochondrial Toxicity. RoFAR Foundation. Pai AB (PI). $31,800. Status: Not Funded

Development of an extemporaneous lanthanum carbonate oral suspension. Shire, Inc. Pai AB (PI), Conner TA, Felton L (Co-I’s) $70,000 Status: Status: Not Funded

2006 Cytokine Activation, Oxidative Stress and Mitochondrial Toxicity Associated with IV Iron Use in

Patients on Hemodialysis. Clinical Translational Science Center Career Development Award. Pai AB (PI) Raj DSC, Walker MK, Shah VO. (Co-Is) Status: Not Funded

Comparison of Hemoglobin Stability, Oxidative Stress and Vascular Reactivity in Diabetic Hemodialysis Patients with Hyporesponse to rHuEPO. Hoffman-LaRoche, Pai AB (PI) $276,000 Status: Not Funded

CONTRACTS AWARDED

2012 A Phase 1, Single-Center, Open-Label, Single-Dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil in Adults Receiving Continuous Renal Replacement Therapy. Forest Research Institute. $224,250, Pai AB (PI), Asif A (Co-I), Cardone KE (Co-I)

2011 A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic

Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression. Otsuka Pharmaceuticals, $26,438 Pai AB (PI)

An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization, Otsuka Pharmaceuticals, $92,000 Pai AB (PI)

2006 Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events

(EVOLVE). Amgen Inc, $213,500, Zager PG, Pai AB (Co-PI)

A Phase III of the Safety and Efficacy of Ferumoxytol Compared with Oral Iron as an Iron Replacement Therapy in Hemodialysis Patients who are Receiving Supplemental Erythropoietin Therapy. Advanced Magnetics. $70,000, Raj DSC (PI), Pai AB (Co-PI)

A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorous in Subjects with Stage


14

3 and 4 Chronic Kidney Disease who Have Elevated Serum Phosphorous Levels. Shire Inc. $52,250 Pai AB (PI), Raj D (Co-I)

2005 An open-label multi-center study to document the efficacy, safety and tolerability of long-term

administration of RO0503821 in patients with chronic renal anemia. Hoffman-LaRoche. 197,455 Raj D (PI), Pai AB (Co-PI)

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in chronic kidney disease patients not receiving dialysis. Amgen,Inc. $50,538 Raj D (PI), Pai AB (Co-PI)

2004 A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the

efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis Hoffman- LaRoche. $247,581, Raj D (PI), Pai AB (Co-PI)

2003 TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Subjects on

Cinacalcet. Phase II trial Amgen, Inc. $70,181 CT Spalding (PI), Pai AB (Co-PI) 2002 “A Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral

Calcimimetic Agent (AMG 073) When Two Different Vitamin D regimens are Used in Subjects with Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD). Phase II Trial Amgen, Inc. $58,090 CT Spalding (PI) Pai AB (Co-PI)

2001 “A Placebo Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety

of an Oral Calcimimetic Agent (073) in Secondary Hyperparathyroidism of Chronic Renal Insufficiency (Hemodialysis and Peritoneal Dialysis)" Phase II Trial. Amgen Inc. $40,220 CT Spalding (PI) Pai AB (Co-PI)

RESEARCH PROJECTS WITH NO FUNDING SOUGHT

Community Pharmacy-based NSAID Avoidance Education for High-Risk Patients. Pai AB (PI), Grabe DW, Cerulli J, Cho S (Co-Is). Status: Publication accepted in Preventing Chronic Disease

A New Tool to Assess Literacy and Numeracy Skills Relating to Medication Labeling in Patients on Dialysis. Cardone K (PI), Parker W, Pai AB, Cho S. (Co-Is). Status: Publication in preparation

Comparison of cefazolin versus nafcillin in treatment of bacteremia in hemodialysis patients. Pai MP (PI), Pai AB (Co-I), Demirovic J (Co-I). Status: Abstract presented

Risk Factors Associated with Hypocalcemia in Hemodialysis Patients on Cinacalcet. Pai AB (PI), Boyd AV (Co-I), McQuade CM (Co-I), Burke R (Co-I), Chavez A (Co-I). Status: Abstract presented.

Retrospective Analysis of Prophylactic Enoxaparin Use in Obese Patients. Pai AB (PI), Anselmo L (Co-I), Horton E (Co-I), Garcia D (Co-I). Status: Abstract presented

Development of a Vancomycin Dosing Protocol in Hi-flux Hemodialysis. Internal Data Collection Project Pai AB (PI), Pai MP (Co-I). Status: Published

Relationship between INR and Access Thrombosis in Hemodialysis Patients on Warfarin. Dialysis Clinics Inc. National Database. Pai AB (PI), R. Brown (Co-I), CT Spalding (Co-I), PG Zager(Co-I). Status: Abstract presented


15

RESEARCH TRAINING

August 2007 Nephrology PRN Mini-Sabbatical Maine Medical Center Research Institute Mentor: Thomas Nolin, Pharm.D., PhD. “Assessment of aminothiol concentrations after IV iron administration”

November 9, 2005 Professional Development Seminar sponsored by Women in Nephrology

American Society of Nephrology Renal Week (Received travel grant to attend)

March 30, 2004 IRB 101

Public Responsibility in Medicine and Research Aug 2001-Oct 2003 University of New Mexico General Clinical Research Center

Scholars Program September 8-10, 2001 Preparing for a Clinical Research Career in Nephrology

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases and the American Society of Nephrology

October 9-10, 2001 Clinical Research Skills Workshop for Investigators

Sponsored by Pfizer INVITED PRESENTATIONS AND CONTINUING EDUCATION

1. Pharmacist-led programs to improve medication safety in kidney disease. 4ª Jornada Integrada de Qualidade em Hemodiálise – Programação, São Paulo, Brazil, June 19, 2015

2. Lipoteichoic acid: potential as a non-invasive marker of biofilm burden. University of São Paulo,

Department of Pharmaceutical Sciences. São Paulo, Brazil, June 19, 2015

3. Clinical Challenges with IV Iron Use in Kidney Disease. GDUFA FY 2015 Regulatory Science Initiatives Part 15 Public Meeting, Silver Spring MD, June 5, 2015

4. Top Ten Reasons to Have a Pharmacist of the ESKD Team. National Kidney Foundation Spring

Clinical Meeting. March 25, 2015, Dallas, Texas

5. Top Ten Nephrotoxic Drugs. National Kidney Foundation Spring Clinical Meeting. March 26, 2015, Dallas, Texas

6. Generic IV Iron Formulations: Black Solutions in a Regulatory Gray Area. National Kidney

Foundation Spring Clinical Meeting. March 28, 2015, Dallas, Texas

7. Keeping Kidneys Safe: Counseling High Risk Patients on NSAID Use to Prevent Kidney Injury. NIH National Kidney Disease Education Program Pharmacy Work Group. CE Program, September 2014

8. Clinical Use of Iron Oxide Nanoparticles in Chronic Kidney Disease. 12th Annual Current Issues

in Medicine Biotech and Pharma. Rensselaer Polytechnic Institute. Troy, NY. September 18, 2014


16

9. Safety of Intravenous Iron: Bench to Bedside. Food and Drug Administration, Office of Generic

Drugs, Science Team. Silver Springs, MD. July 28, 2014 10. Medication Management in Chronic Kidney Disease: A Dam Ready to Break. Southern

Association of Medicaid Pharmacy Administrators. Annual Meeting. Key West, FL. July 22, 2014 11. Medication Management in Chronic Kidney Disease: Pharmacotherapy in a House of Mirrors.

APhA Annual Meeting and Exposition Orlando, FL, March 31, 2014 12. Safety Concerns with Intravenous Iron: Bench to Bedside. 3ª Jornada Integrada de Qualidade em

Hemodiálise – Programação, São Paulo, Brazil, April 4th, 2014 13. Calcium and Phosphorus Metabolism in Chronic Kidney Disease and the Management of

Hyperphosphatemia. Power Pak CE. November 11, 2013 14. Safety Intravenous Iron: Bench to Bedside. SUNY Upstate Medical Center, Nephrology Grand

Rounds. Syracuse, NY. October 8, 2013 15. Evidence-Based Screening and Prevention Strategies: Chronic Kidney Disease. Clinical

Reasoning Series. American College of Clinical Pharmacy Annual Meeting. Speaker and Moderator. October 12, 2013, Albuquerque, NM.

16. New an Emerging Agents for Anemia of CKD: Time for a New Direction? American College of

Clinical Pharmacy Annual Meeting. Speaker. October 15, 2013, Albuquerque, NM. 17. Safety Considerations for IV Iron Products: Tips for Current Practice. Albany College of

Pharmacy and Health Sciences. April 28, 2013. Albany, NY ACPE 1.0 contact hour 18. Role of Pharmaceutical Care on Drug Use and Hospitalizations in ESRD Patients. American

Society of Nephrology, Renal Week. November 2, 2012, San Diego, CA 19. Safety Considerations for IV Iron Products: Tips for Current Practice. American Society of Health-

systems Pharmacists Mid Year Clinical Meeting and Exhibition. December 6, 2011 New Orleans, LA

20. Creatinine Clearance Equations-Tips for Current Practice. Albany College of Pharmacy and

Health Sciences. October 23, 2011. Albany, NY ACPE 1.0 contact hour 21. Adverse Events Associated with Intravenous Iron Therapy. American Society of Health-systems

Pharmacists Mid Year Clinical Meeting and Exhibition. December 9, 2009, Las Vegas, NV ACPE 3.0 contact hours

22. Chronic Kidney Disease- Patient Management Pearls. Pharmacy Practice Institute, Albany

College of Pharmacy and Health Sciences, March 21, 2009 ACPE 1.0 contact hour 23. Contemporary issues in drug dosing in kidney disease. Elmhurst Hospital, Queens, NY. May 16,

2012 24. Safety Intravenous Iron: Contemporary Safety Concerns, Amgen Regional Medical Science

Liaisons meeting. Live Webinar July 15, 2011 25. Safety Intravenous Iron: Bench to Bedside, World Congress of Nephrology, Renal Pharmacists

Network, April 8, 2011, Vancouver, BC 26. Intravenous iron in hemodialysis patients-too much of a good thing? American Chemical Society,

March 17, 2010, Albany, NY


17

27. Chronic Kidney Disease Patients (CKD 3 and 4): Clinical Pearls for Bridging the Gap between

Hospitalization and Outpatient Care. American College of Clinical Pharmacy Annual Meeting. Anaheim, CA. October 20, 2009

28. Updates in Anemia of CKD: New ESA and Iron Products. Nephrology Noon Conference.

University of New Mexico Health Sciences Center March 31, 2008. 29. Chronic Kidney Disease- a case-based, active learning approach. Program Chair, Speaker and

Case Moderator. April 19, 2008, Albuquerque, NM ACPE 8.75 contact hours 30. Therapeutic Advances in Chronic Kidney Disease: Management of Anemia. Medscape Audio

Cybersession. Recorded June 15, 2007. ACPE/CME 1.0 contact hour 31. Use of Vitamin D Analog Therapy in CKD. Nephrology Noon Conference. University of New

Mexico Health Sciences Center December 12, 2006. 32. Phosphate Binder Therapy in CKD. Nephrology Noon Conference. University of New Mexico

Health Sciences Center December 11, 2006 33. Health Care Disparities in Chronic Kidney Disease. American College of Clinical Pharmacy

Annual Meeting October 28, 2006, St. Louis, MO. 34. Anemia of CKD. Nephrology Noon Conference. University of New Mexico Health Sciences

Center. August 28 and 30, 2006 35. Broader Roles of Vitamin D in Patients with CKD. American College of Clinical Pharmacy,

Nephrology PRN Business and Networking Forum. April 8, 2006 36. Intravenous Iron Therapy: Current Data on Oxidative Stress and Infection. Nephrology Noon

Conference. University of New Mexico Health Sciences Center. March 20, 2006 37. Anemia of Chronic Kidney Disease: Pathophysiology and Treatment: New Mexico Society of

Health-systems Pharmacists. May 18 and June 8, 2006, Albuquerque, NM ACPE 176-000-06- 010-L01

38. Role of Cinacalcet in Management of Secondary Hyperparathyroidism. November 18, 2004,

Dialysis Clinic Inc., Nurse Managers, Albuquerque,NM 39. Significant Papers in Pharmacotherapy: Nephrology. October 25, 2004, American College of

Clinical Pharmacy Annual Meeting, Dallas, TX. 40. Iron and Oxidative Stress in Hemodialysis Patients. April 15, 2004, New Mexico Center for

Environmental Health Sciences. Renal-Cardiovascular Subcore 41. Enhancing Patient Adherence: The Role of a Pharmacist. Zambian Pharmaceutical Society

Annual General Meeting. June 14, 2003 Mulungushi International Conference Centre, Lusaka, Zambia

42. Treatment of Hypertension in the Hemodialysis Population. Dialysis Clinic, Inc. Nurse Managers

Meeting. April 15, 2003, Dana Point, CA 43. Anemia of Chronic Kidney Disease: Strategies for Optimizing Treatment. Utah Society of Health-

systems Pharmacists. September 7, 2002, Sandy, Utah. ACPE 167-000-02-006-L01


18

44. Emerging Treatment for Renal Osteodystrophy. Nephrology Noon Conference. University of New Mexico Health Sciences Center. October 28, 2002

45. Anemia of CKD, New Strategies for Treatment. Nephrology Noon Conference. University of New

Mexico Health Sciences Center. October 16, 2002

46. Treatment of Hypertension in the Renal Failure Patient. American Nephrology Nurses Association (ANNA), Western Chapter, September 29, 2002, Albuquerque, NM

47. Pharmacokinetic and Pharmacodynamic Considerations in Renal Failure. Nephrology Noon

Conference. University of New Mexico Health Sciences Center. August 28, 2002

48. Anemia of Chronic Kidney Disease: Strategies for Optimizing Treatment. New Mexico Society of Health-systems Pharmacists. July 11, 2002, Albuquerque, NM. ACPE 176-000-02-008-LO1

49. Pharmacological Management of Hypertension in Hemodialysis Patients. New Mexico Council on

Renal Nutrition, July 19, 2002, Albuquerque,NM

50. Optimizing Anemia Management in ESRD, New Mexico Society of Health-systems Pharmacists Annual Meeting, October 8, 2001, Albuquerque, NM

51. Treatment of Hypertension in the Hemodialysis Population. Fellowship Seminar,

Faculty/Residents University of Illinois at Chicago, November 1999

52. Management of Anemia and Bone Disease in ESRD. Faculty/PharmD students University of Illinois at Chicago, August 1999, February 2000

53. Evaluating Diuretic Resistance and Implementation of Therapeutic Substitution; Torsemide for

Bumetanide. Barton AB, Carson J, Lombardi TP. Third Annual Sister Katherine Graber Research Forum. 1.Complementary Methods of Cardiac Care Delivery, Albany, New York, April 1997; 2.16th Annual Eastern States Conference for Pharmacy Residents and Preceptors. Baltimore, Maryland, May 1997.

54. Anti-Tumor Necrosis Factor in Treatment of Rheumatoid Arthritis. Doctor of Pharmacy Seminar,

Albany College of Pharmacy, Albany, NY November 1997

55. Torsemide as An Alternative to Bumetanide.St. Peter’s Hospital Department of Nursing, Albany, NY February 1997

56. Circumventing Diuretic Resistance.1. St. Peter’s Hospital Staff, Albany, NY September 1996 2.

St. Peter’s Hospital Medicine and Family Practice Residents, Albany, NY February, 1997

57. Pharmacokinetics of Meperidine in Fetal Sheep. Albany College of Pharmacy Biopharmaceutics, Albany, NY November 1995

TEACHING

January 2011-present Integrated Problem Solving 6 Course Coordinator and Section Facilitator

January 2011-present Advanced Nephrology

Acute Kidney Injury, Clinical Pharmacokinetics PharmD (elective)

Aug 2010-Aug 2013 Pharmacology, Therapeutics, Pathophysiology and

Medicinal Chemistry


19

Prevention of Progression of CKD, Anemia, Acute Kidney Injury Acid-Base Disorders, Drug-induced Kidney Disease, Electrolyte Disorders

Jan 2010-present Nephrology Patient Care

Albany College of Pharmacy and Health Sciences Acute Kidney Injury, Clinical Pharmacokinetics PharmD (elective)

Feb 2009-present Advanced Pharmacy Practice Experience

Albany College of Pharmacy and Health Sciences Clinical Nephrology 10-12 students per year

Feb 2009 Pharmacotherapy IV

Albany College of Pharmacy and Health Sciences Pharmacokinetics and drug metabolism in chronic kidney disease, acute kidney injury

Jan 2009-May 2009 Seminar I

Albany College of Pharmacy and Health Sciences Oct 2008-Dec 2008 Seminar II

Albany College of Pharmacy and Health Sciences Feb 2007, Sept 2009, University of Florida, Working Professionals Doctor of Pharmacy Degree Sept 2011 Program, End-stage Renal Disease and Dialysis

2008 Pharm 739 Pharmacotherapy I

University of New Mexico, College of Pharmacy, Albuquerque, NM Renal Module: Acute and Chronic Kidney Disease, Drug-Induced Renal Disease, Dialysis-Related Complications

2007-2008 Pharm 726 Pharmacokinetics and Biopharmaceutics

University of New Mexico, College of Pharmacy, Albuquerque, NM Drug Dosing in Renal Failure, Quantification of Renal Function

Jan 2007 Pharm 798 Problems in Pharmacy

Students gain early clinical experience with patient and health professional interaction, critical literature review and patient presentation skills at an outpatient hemodialysis unit.

2002-2004 Pharm 716 Practical Patient Experience

University of New Mexico, College of Pharmacy, Albuquerque, NM 6 students per year

2002-2007 Pharm 751 Pharmacotherapy

University of New Mexico, College of Pharmacy, Albuquerque, NM Renal Module: Acute and Chronic Kidney Disease, Drug-Induced Renal Disease, Dialysis-Related Complications, Glomerulonephritis

2001-present Pharm 770 Clinical Clerkships

University of New Mexico, College of Pharmacy, Albuquerque, NM 6 to 8 students per year

2001-2007 Pharm 745 Clinical Pharmacokinetics

University of New Mexico, College of Pharmacy, Albuquerque, NM


20

Drug Dosing in Renal Failure, Quantification of Renal Function

2001-2007 Pharm 711/712, 721/722 731 Problem-Based Learning University of New Mexico, College of Pharmacy, Albuquerque, NM 14 to 16 students per year

Jan – Feb 2000/2001 PHAR 407 Principles of Drug Action and Therapeutics

University of Illinois, College of Pharmacy, Chicago, IL Drug Use in Renal Failure: Teaching Assistant Chronic Renal Failure: Lecturer Acute Renal Failure: Teaching Assistant

Feb 2000/2001 PMPR 370 Pharmacy Grand Rounds

University of Illinois, College of Pharmacy, Chicago, IL Anemia and Bone Disease in End-Stage Renal Disease: Lecturer

Aug- Sept 1999 Ambulatory Care Lecture Series

University of Illinois, College of Pharmacy, Chicago, IL End-Stage Renal Disease

TRAINEES AND MENTEES

July 2015-present Co-Director, PGY2 Nephrology Residency Nicole Wegryzn, Pharm.D. (2015-2016)

May 2014-August 2014 Research Mentor: University of São Paulo fellowship program

Geisa Otani August 2013 Early Patient Care Experiential Elective

Participants: Adam Hoye-Simek, Class 2016 David Hughes, Class 2016 Jeffrey Bettinger Class 2017 Andrea Glowgowski Class 2017 Christopher Bartolillo Class 2017

July 2013-June 2014 Mentor, Teaching and Learning Program

Amanda Rennick, Pharm.D. PGY 1 resident Stratton VA Medical Center, Albany, NY

July 2013-June 2014 Director, Nephrology Pharmacotherapy Residency

Soo Min Cho, Pharm.D. (2013-2014) Feb 2013-Sept 2013 Primary Mentor: University of São Paulo fellowship program

Daniele Alcantara July 2012-2013 Director, Nephrology Pharmacotherapy Fellowship

Fellows: Adinoyi Garba, PharmD (2012-2013) 2009-present Independent Research Study

Heena Patel, Class 2012 Dara Becker, Class 2013 Natsuki Kubotera, Class 2013 Alex Prokopienko, Class 2014 Mara Garfinkel Class of 2016


21

2009-present Mentor, Summer Research Award

Albany College of Pharmacy and Health Sciences Heena Patel, Class 2012 Dara Becker, Class 2013 Natsuki Kubotera, Class 2013 Alex Prokopienko, Class 2014 Bradley Teoh, Class 2014

February 2009-2014 Director, Clinical Pharmacy Research Training Program

Albany College of Pharmacy and Health Sciences Program participants: Heena Patel, Class 2012 Natsuki Kubotera, Class 2013 Alex Prokopienko, Class 2014

July 2006-Jun 2008 Director, Nephrology Pharmacotherapy Fellowship

University of New Mexico, College of Pharmacy Fellows: Todd Conner, Pharm.D. (2006-2008)

May 2006-Oct 2008 Director and Preceptor, Early Patient-Oriented Care Internship

University of New Mexico, College of Pharmacy Program participants: Alex Boyd, Class 2008 Summer Bryan, Class 2009 Alicia Chavez, Class 2009 Vienna Heindl, Class 2009 Charles McQuade, Class 2010 Maggie Post, Class 2010 Lynette Wasson, Class 2009

Sept 2005-Oct 2008 Director, Clinical Pharmacy Research Training Program

University of New Mexico, College of Pharmacy Program participants: Alex Boyd, Class 2008 Charles McQuade Class 2010 Alicia Chavez, Class 2009 Gavyn Thomas Class 2013 Marshall Caraveo pre-pharmacy

Jul 2003-Jul 2005 Director, Specialized Residency in Nephrology Pharmacotherapy

University of New Mexico, College of Pharmacy Residents: Joseph Depczynski, Pharm.D. (2003-2004)

Isela Martinez, Pharm.D. (2004-2005) GRADUATE STUDENTS

August 2009 Jaclyn Hosmer (MS in Pharmaceutical Sciences)

Thesis Committee TEACHING TRAINING

August 4-6, 2002 Jump Start for New Faculty

Albany College of Pharmacy, Albany, NY


22

EDITORIAL

September 2015 Co-Editor, Advances in Chronic Kidney Diseases Special Issue: Pharmacogenomics and Personalized Medicine in CKD

May 2015 Abstract Category Chair

Pharmacokinetics (PK)/Pharmacodynamics (PD)/Pharmacogenomics American Society of Nephrology

April 2015 Editorial Board, Brazilian Journal of Nephrology

3-year appointment May 2014 Abstract Category Chair

CKD: Health Services, Prevention American Society of Nephrology

August 2013 PSAP Reviewer

“Chronic Diseases-Chronic Kidney Disease” May 2013 Abstract Reviewer

American Society of Nephrology July 2012 Editorial Board, Advances in Chronic Kidney Disease

3-year appointment

June 2011 Editorial Board, Journal of Nephrology and Therapeutics

September 2010 Co-Editor, Advances in Chronic Kidney Diseases Special Issue: Optimizing Pharmacotherapy in CKD

2005 Reviewer, National Kidney Foundation Kidney Disease Outcomes Quality

Initiative (K/DOQI) clinical practice guidelines “Anemia in Chronic Kidney Disease”

2004 Reviewer: Immunosuppressants. Contemporary Nephrology Nursing. Pitman,

NJ: American Nephrology Nurses Association, 2006 Pitman, NJ: American Nephrology Nurses Association.

2003 Reviewer, National Kidney Foundation Kidney Disease

Outcomes Quality Initiative (K/DOQI) clinical practice guidelines “Blood Pressure Management and Use of Antihypertensive Agents in Chronic Kidney Disease”

2002-2008 Editorial Advisory Board, Dialysis and Transplantation

2002-2008 Associate Editor, Kidney: A Current Survey of World Literature

2000- 2002 Editorial Assistant, Kidney: A Current Survey of World Literature

JOURNALS REVIEWED

Clinical Journal of American Society of Nephrology Clinical Pharmacokinetics


23

Nanomedicine BMC Nephrology Pediatric Nephrology Hemodialysis International Journal of Clinical Pharmacology Health Affairs Journal of Managed Care Pharmacy Journal of Renal Nutrition Journal of Clinical Pharmacology Clinical Pharmacology and Therapeutics American Journal of Kidney Disease American Journal of Health-Systems Pharmacy Peritoneal Dialysis International Kidney International American Journal of Nephrology International Journal of Clinical Practice Dialysis and Transplantation Pharmacotherapy Journal of Medical Economics

PROFESSIONAL SERVICE

February 2015 Invited member, 2016 National Kidney Foundation Spring Clinical Meeting

Programming Committee March 2014 Invited member, Kidney Disease Improving Global Outcomes (KDIGO)

Controversies Conference on Iron Management in Chronic Kidney Disease, March 29-31, 2014, San Francisco, CA.

February 2014 Invited member, 2015 National Kidney Foundation Spring Clinical Meeting

Programming Committee August 2014 Member, Women Faculty Special Interest Group (SIG)

American Association of Colleges of Pharmacy August 2014 Member, Global Pharmacy Education (SIG)

American Association of Colleges of Pharmacy May 2013 Invited member, ASN Kidney Week Review Task Force

December 2012 ACCP Volunteer Recognition Program, recognition for contributions to NY State

Chapter of ACCP Dec 2012-Dec 2013 President

New York State Chapter of ACCP January 2012 Chair, Pharmacy Work Group

NIH-National Kidney Disease Education Program (NKDEP) December 2011 President-elect 2012

New York State Chapter of ACCP Oct 2011-Sep 2014 Member, American Society of Nephrology

Dialysis Advisory Group


24

August 2011 Member, Coordinating Panel

NIH-National Kidney Disease Education Program (NKDEP) August 2011 Member, Programming Committee

New York State Chapter of ACCP June 2011-present Chair

New York State Kidney Disease Coalition March 2011 Member, Renal Research Institute

Programming Committee September 2010 Member, Pharmacy Advisory Committee

NIH-National Kidney Disease Education Panel April 2010 Chair, ACPE Self Study

Curriculum subcommittee August 2009 Advisor, ACCP Student Affiliate/Chapter

Albany College of Pharmacy and Health Sciences August 2009 Member, Graduate Admissions Committee

Albany College of Pharmacy and Health Sciences June 2009-Nov 2012 Co-Chair

Pharmacy Curriculum Committee Albany College of Pharmacy and Health Sciences

March 2009 Member, Graduate Council

Albany College of Pharmacy and Health Sciences Mar 2009-Mar 2010 Member, Institutional Biosafety Committee

Albany College of Pharmacy and Health Sciences Oct 2008- Nov 2012 Pharmacy Curriculum Committee, Member

Albany College of Pharmacy and Health Sciences October 2008 College of Pharmacy Student Liaison

American College of Clinical Pharmacy Albany College of Pharmacy and Health Sciences

August 2007 OPEC Research Sub-committee

University of New Mexico

September 2006 Pharmacy Practice Reimbursement Committee

August 2006 College of Pharmacy Student Liaison American College of Clinical Pharmacy University of New Mexico

July 2005 Pharmacy Administration Faculty Search committee

April 2005 Contributor Center for Medicaid and Medicare Services ESRD Program Technical Expert Panel


25

Apr 2005 Member

Clinical Trials Center Steering Committee University of New Mexico Health Sciences Center

Oct 2005-Oct 2006 Chair

Nephrology Practice and Research Network American College of Clinical Pharmacy

Oct 2003-2005 Chair, Communications Committee


2003-2005 Associate Member

New Mexico Center for Environmental Health Sciences Cardiovascular/Renal Toxicology Subcore NIEHS Grant P30 ES-012072

2003-2005 Coordinator, New Mexico Residents’ and Fellows’ Journal Club

2003-2006 Strategic Planning Committee University of New Mexico, College of Pharmacy, Albuquerque, NM

2003 Jul 2006 Residency Committee

University of New Mexico, College of Pharmacy, Albuquerque, NM 2002 Oct 2003 Communications Committee


2002 Psychiatric Faculty Search Committee

University of New Mexico, College of Pharmacy, Albuquerque, NM 2001-2003 Student Services Committee

University of New Mexico, College of Pharmacy, Albuquerque, NM COMMUNITY SERVICE

August 2015 Summerfest 2015, Centro Civico, Amsterdam, NY

Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy. Provides free screening to underserved populations.

September 2014 2014 Health Care Expo, Albany College of Pharmacy and Health Sciences

Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy. Provides free screening to underserved populations.

October 2014 O+Festival, Kingston, NY

The O+ festival provides free health service and counseling for local artists and underserved populations. Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy.

October 2014 Catwalk for Kidneys, Saratoga, NY

Participant to support Northeast Kidney Foundation (NeKF)


26

2008-present Visiting Scientist

Voorheesville Elementary School Science Fair June 2012 Young Women in Science Program

Bard College at Simon’s Rock Great Barrington, MA

May 2007 Special Awards Judge

Intel International Science and Engineering Fair Albuquerque, NM

2005-2008 Grant Coordinator

The Montessori Elementary School Identifed, coordinated and wrote grants to support school development and activities Funded grants: Jul 2006 Elementary Arts Education Program, New Mexico Public Education Department, $29,511 Submitted grants: PNM Classroom innovation 2006, 2008 (funded $3,000) BP A+ for Energy, 2008

2002 Judge, Medicine/Microbiology/Gerontology

Rio Rancho High School Research Expo HONORS AND AWARDS

2014 ACCP Member Spotlight, September 2014 2014 ACCP Volunteer Recognition

2014 Advisor of the Year, Albany College of Pharmacy and Health Sciences

2010 Fellow, American College of Clinical Pharmacy

2004 Fellow, American Society of Nephrology

1999 Pfizer Experiential Award for Clerkship Excellence

1996 APhA-ASP Professionalism Award Sponsored by McNeil

1994 Rho Chi Pharmaceutical Honor Society

1993-1999 Deans List Albany College of Pharmacy

1993 Dutchess United Educators Award for Academic Excellence

1991-1993 Deans List Dutchess Community College

PROFESSIONAL AFFILIATIONS

2011-present Member, International BioIron Society 2009-present Member

New York State Chapter of the American College of Clinical Pharmacy


27

2009-present Member, American Thoracic Society

2002-present American Heart Association, Council on the Kidney in Cardiovascular

Disease, Member 2001-present American Association of Colleges of Pharmacy, Active

Member 2001-present National Kidney Foundation

2001-present International Society of Nephrology

1999- present American Society of Nephrology,

Fellow

2001-2008 New Mexico Society of Health-systems

Pharmacists 2003-present American College of Clinical Pharmacy, Full

Member

1997-2003 American College of Clinical Pharmacy, Associate

Member 1996-1999 Pharmaceutical Society of the State of New York

1996-present American Society of Health-system Pharmacists 1996-1999 New York State Council of Health-systems

Pharmacists 1994 Rho Pi Phi Pharmaceutical Fraternity

1994 Rho Chi Pharmaceutical Honor Society, Gamma Gamma Chapter 1995-1996 Secretary

August 21, 2015

Documents

Amy Barton Pai - UM College of Pharmacy · Amy Barton Pai. Home Address Work Address 2222 New Scotland Road Albany College of Pharmacy . Voorheesville, NY 12186 and Health Sciences